MSH6 and Lynch syndrome: To adapt to this change, the initial recruitment target of 600 ARRs in total was adopted to 490 ARRs in the most prioritized subgroup, i.e., families with a pathogenic variant identified in a high-risk gene (hereditary breast and ovarian cancer and Lynch syndrome: BRCA1, BRCA2, PALB2, MSH2, MSH6, MLH1, or PMS2).